NDA 020356 · Azurity
Sular
Nisoldipine · Oral · Dihydropyridine Calcium Channel Blocker
NovelLast checked: Nov 19, 2026Latest source record: Jun 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Feb 2, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
0 Phase 3, 0 recruiting
FAERS reports
1,198
780 serious, 123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 12, 2026.
INDICATIONS AND USAGE SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other anti-hypertensive agents.
Mechanism: Mechanism of Action Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. It reversibly competes with other dihydropyridines for binding to the calcium channel. Because the contractile process of vascular smooth muscle is dependent upon the movement of extracellular calcium into the muscle through specific ion channels, inhibition of the calcium channel results in dilation of the arterioles. In vitro studies show that...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
8 products under this application
- SULAR · NISOLDIPINE 25.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- SULAR · NISOLDIPINE 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- SULAR · NISOLDIPINE 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- SULAR · NISOLDIPINE 17MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
- SULAR · NISOLDIPINE 34MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
- SULAR · NISOLDIPINE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- SULAR · NISOLDIPINE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- SULAR · NISOLDIPINE 8.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nisoldipine" as an intervention, any sponsor and status, largest first.
Mylan Pharmaceuticals IncIndustry
NCT00979537 · 83 participants · Start Mar 2007 · Primary completion Mar 2007
Drug: Nisoldipine Extended-release Tablets, 40 mg; Sular Tablets, 40 mg · For: Healthy
Sites: Fargo, North Dakota
Mylan Pharmaceuticals IncIndustry
NCT00985660 · 78 participants · Start Jun 2007 · Primary completion Jul 2007
Drug: Nisoldipine Extended-release Tablets, 30 mg; Sular® Extended Release Tablets, 30 mg · For: Healthy
Sites: Fargo, North Dakota
Steno Diabetes Center CopenhagenAcademic, hospital or other
NCT00311870 · 52 participants · Start Mar 1993
Drug: nisoldipine; lisinopril · For: Diabetic Nephropathy
Sites: Gentofte Municipality, Denmark
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated HypertensionCompleted
Medical University of South CarolinaAcademic, hospital or other
NCT00684489 · 52 participants · Start Sep 2003 · Primary completion Mar 2005
Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med. · For: Hypertension
Mylan Pharmaceuticals IncIndustry
NCT00730197 · 48 participants · Start Feb 2007 · Primary completion Mar 2007
Drug: Albuterol Sulfate Extended-Release Tablets 8 mg; VoSpire® ER Tablets 8 mg · For: Healthy
Sites: Fargo, North Dakota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea89
- drug ineffective79
- dizziness77
- headache76
- fatigue74
- renal failure65
- pain64
- dyspnoea63
- asthenia62
- diarrhoea59
- anxiety54
- myocardial infarction54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 58 |
| 2005 | 49 |
| 2006 | 82 |
| 2007 | 70 |
| 2008 | 81 |
| 2009 | 106 |
| 2010 | 111 |
| 2011 | 83 |
| 2012 | 85 |
| 2013 | 40 |
| 2014 | 54 |
| 2015 | 55 |
| 2016 | 51 |
| 2017 | 45 |
| 2018 | 58 |
| 2019 | 65 |
| 2020 | 28 |
| 2021 | 21 |
| 2022 | 15 |
| 2023 | 9 |
| 2024 | 15 |
| 2025 | 10 |
| 2026 | 7 |
Recalls
1 FDA enforcement reports for this application.
Jul 24, 2015 · Class III · Terminated
Failed Dissolution Specifications
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sular (Nisoldipine)
2024 spending
$319K
Beneficiaries
26
126 claims
Per beneficiary
$12,271
$30.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $602,980 |
| 2021 | $517,711 |
| 2022 | $473,530 |
| 2023 | $351,576 |
| 2024 | $319,058 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The pharmacology of nisoldipine.
Knorr A · Cardiovasc Drugs Ther 1987 · Clinical Trial, Comparative Study
- Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.
Uesawa Y, Takeuchi T, Mohri K · Curr Pharm Biotechnol 2012 · Meta-Analysis
- Nisoldipine in primary Raynaud's phenomenon.
Challenor VF, Waller DG, Francis DA, et al. · Eur J Clin Pharmacol 1987 · Clinical Trial, Controlled Clinical Trial
- Interaction between grapefruit juice and diazepam in humans.
Ozdemir M, Aktan Y, Boydag BS, et al. · Eur J Drug Metab Pharmacokinet 1998 · Clinical Trial, Randomized Controlled Trial
- Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease.
Silke B, Frais MA, Midtbo KA, et al. · Clin Pharmacol Ther 1987 · Clinical Trial, Comparative Study
- Telmisartan improves endothelial function in patients with essential hypertension.
Benndorf RA, Appel D, Maas R, et al. · J Cardiovasc Pharmacol 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.